List Price - $1,140.00
The DuraClone B27 Reagent Kit comprises a two-color, immunofluorescence stain, suitable for detecting the HLA-B27 antigen expression in erythrocyte-lysed, human whole blood samples (for example, a lyse and no wash protocol), using a flow cytometer. This reagent is not intended to be used to determine the HLA-B27 tissue group.
The Human Leukocyte Antigen (HLA) B27 is a Class I surface antigen encoded by the B locus in the major histocompatibility complex (MHC) that presents microbial antigens to T-lymphocytes. The onset of seronegative spondyloarthropathies that include ankylosing spondylitis, Reiter's disease, psoriatic arthritis and inflammatory bowel disease are associated with the expression of HLA-B27 antigen on T-lymphocytes. Screening for HLA-B27 is thus of clinical relevance in conjunction with the symptomatic presentation of the disorder. Micro-lymphotoxicity tests are conventionally used in HLA-typing but are time-consuming and expensive. Flow cytometry has gradually evolved into a faster and reliable method for screening samples for HLA-B27 antigen.
T-lymphocytes selected through gating of the CD3+ specific population are analyzed for staining by HLA-B27 conjugates. It has been demonstrated that this pre- selection of T-lymphocytes increases the specificity of the test by eliminating the background attributed to other leukocyte populations. Another method of lowering the risk of false-positives is by the addition of an Anti-B7 antibody to the reagent cocktail. The Anti-B7 antibody competes with the Anti-B27 antibody for the B7 antigen and in this manner, suppressing the incidence of cross- reactivity of Anti-B27 antibodies to B7 antigens.
The DuraClone B27 Reagent Kit contains two clones of the Anti-HLA-B27 antibody and an Anti-B7 antibody. The presence of these antibodies improves the specificity of the reagent. The Anti-B7 antibody binds preferentially to the B7 antigen, thus reducing cross-reactivity.
The test result is a direct extrapolation of the fluorescent staining intensity of the HLA-B27 conjugates with respect to a cutoff value.
A protocol, specific to BD Biosciences* instruments, is detailed in the B27 Reagent Kit IFU (Instruction for Use).
NOT ALL PRODUCTS ARE AVAILABLE IN ALL COUNTRIES
PRODUCT AVAILABILITY AND REGULATORY STATUS DEPENDS ON COUNTRY REGISTRATION PER APPLICABLE REGULATIONS
The listed regulatory status for products correspond to one of the below:
IVD: In Vitro Diagnostic Products. These products are labeled "For In Vitro Diagnostic Use."
ASR: Analyte Specific Reagents. These reagents are labeled "Analyte Specific Reagents. Analytical and performance characteristics are not established."
CE: Products intended for in vitro diagnostic use and conforming to European Directive (98/79/EC). (Note: Devices may be CE marked to other directives than (98/79/EC)
RUO: Research Use Only. These products are labeled "For Research Use Only. Not for use in diagnostic procedures."
LUO: Laboratory Use Only. These products are labeled "For Laboratory Use Only."
No Regulatory Status: Non-Medical Device or non-regulated articles. Not for use in diagnostic or therapeutic procedures.